principals have over 40 years of experience in the clinical development of psychotropic drugs and have conducted pivotal studies of many drugs approved by the FDA in psychiatry. They have conducted studies in depression, anxiety, schizophrenia, bipolar disorder, social phobia and sleep disorders. They also have over 40 years of experience in in-patient and out-patient psychiatry, have intimate knowledge of the treatment of Central Nervous System (“CNS”) disorders and have analyzed many potential psychotropic compounds from the standpoint of receptor activity, efficacy, tolerability, side effect/benefit ratio, formulation, ease of administration, cost, and ease of manufacturing.